NO960775L - Anvendelse av kinoksaliner i kombinasjon med proteaseinhibitorer som legemiddel for behandling av AIDS og/eller HIV-infeksjoner - Google Patents

Anvendelse av kinoksaliner i kombinasjon med proteaseinhibitorer som legemiddel for behandling av AIDS og/eller HIV-infeksjoner

Info

Publication number
NO960775L
NO960775L NO960775A NO960775A NO960775L NO 960775 L NO960775 L NO 960775L NO 960775 A NO960775 A NO 960775A NO 960775 A NO960775 A NO 960775A NO 960775 L NO960775 L NO 960775L
Authority
NO
Norway
Prior art keywords
quinoxalins
aids
drug
treatment
combination
Prior art date
Application number
NO960775A
Other languages
English (en)
Other versions
NO960775D0 (no
Inventor
Arnold Paessens
Martin Blunck
Gunther Riess
Jorg-Peter Kleim
Manfred Rosner
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NO960775D0 publication Critical patent/NO960775D0/no
Publication of NO960775L publication Critical patent/NO960775L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det er beskrevet anvendelsen av kinoksaliner l kombinasjon med protease-lnhlbltorer som legemiddel for behandling av AIDS og/eller HIV-lnfeksJoner.
NO960775A 1995-02-27 1996-02-26 Anvendelse av kinoksaliner i kombinasjon med proteaseinhibitorer som legemiddel for behandling av AIDS og/eller HIV-infeksjoner NO960775L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19506742A DE19506742A1 (de) 1995-02-27 1995-02-27 Verwendung von Chinoxalinen in Kombination mit Protease-Inhibitoren als Arzneimittel zur Behandlung von AIDS und/oder HIV-Infektionen

Publications (2)

Publication Number Publication Date
NO960775D0 NO960775D0 (no) 1996-02-26
NO960775L true NO960775L (no) 1996-08-28

Family

ID=7755115

Family Applications (1)

Application Number Title Priority Date Filing Date
NO960775A NO960775L (no) 1995-02-27 1996-02-26 Anvendelse av kinoksaliner i kombinasjon med proteaseinhibitorer som legemiddel for behandling av AIDS og/eller HIV-infeksjoner

Country Status (19)

Country Link
EP (1) EP0728481A3 (no)
JP (1) JPH08245392A (no)
KR (1) KR960030951A (no)
CN (1) CN1141196A (no)
AR (1) AR003923A1 (no)
AU (1) AU710158B2 (no)
BR (1) BR9600809A (no)
CA (1) CA2170222A1 (no)
CZ (1) CZ57896A3 (no)
DE (1) DE19506742A1 (no)
FI (1) FI960850L (no)
HR (1) HRP960070A2 (no)
HU (1) HUP9600455A3 (no)
IL (1) IL117247A (no)
NO (1) NO960775L (no)
NZ (1) NZ286058A (no)
PL (1) PL312908A1 (no)
SK (1) SK25196A3 (no)
ZA (1) ZA961516B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998020888A1 (en) * 1996-11-08 1998-05-22 Japan Energy Corporation Aids remedy
DE19703131A1 (de) * 1997-01-29 1998-07-30 Bayer Ag Verwendung von Chinoxalin in Dreier-Kombination mit Protease-Inhibitoren und Reverse Transkriptaseinhibitoren als Arzneimittel zur Behandlung von AIDS und/oder HIV-Infektionen
US6635626B1 (en) 1997-08-25 2003-10-21 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
US6235740B1 (en) 1997-08-25 2001-05-22 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
ES2324846T3 (es) * 1998-03-04 2009-08-17 Bristol-Myers Squibb Company Inhibidores de la proteina tirosina quinasa de imidazopirazina heterociclo-sustituida.
WO2000018384A2 (en) * 1998-09-28 2000-04-06 Glaxo Group Limited Antiviral combinations comprising (s)-2-ethyl-7-fluoro-3-oxo-3,4-dihydro-2h-quinoxaline-1-carboxylic acid isopropyl ester and amprenavir
GB9911887D0 (en) * 1999-05-21 1999-07-21 Glaxo Group Ltd Methods and medicaments for post exposure prophylaxis of an hiv infection
DE10013318A1 (de) * 2000-03-17 2001-09-20 Merck Patent Gmbh Formulierung enthaltend Chinoxalinderivate
CN1738797A (zh) 2002-11-19 2006-02-22 阿基里昂药品公司 取代的芳基硫脲和相关的化合物,病毒复制的抑制剂
TW200600492A (en) 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
US7351709B2 (en) 2004-06-09 2008-04-01 Wyeth Estrogen receptor ligands
CN105229002A (zh) * 2012-12-20 2016-01-06 拜耳医药股份有限公司 抑制bet蛋白的二氢吡啶并吡嗪酮
DE102017005089A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one
DE102017005091A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substituierte 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT509398E (pt) * 1991-04-15 2002-02-28 Aventis Pharma Gmbh Quinoxalinas processo para a sua preparacao e sua utilizacao

Also Published As

Publication number Publication date
JPH08245392A (ja) 1996-09-24
PL312908A1 (en) 1996-09-02
HUP9600455A3 (en) 1998-04-28
ZA961516B (en) 1996-09-03
CZ57896A3 (en) 1996-09-11
HRP960070A2 (en) 1997-10-31
BR9600809A (pt) 1997-12-23
IL117247A (en) 2000-10-31
CA2170222A1 (en) 1996-08-28
SK25196A3 (en) 1997-05-07
FI960850A7 (fi) 1996-08-28
HU9600455D0 (en) 1996-04-29
KR960030951A (ko) 1996-09-17
AU710158B2 (en) 1999-09-16
FI960850L (fi) 1996-08-28
NO960775D0 (no) 1996-02-26
EP0728481A3 (de) 1998-07-08
FI960850A0 (fi) 1996-02-23
DE19506742A1 (de) 1996-08-29
CN1141196A (zh) 1997-01-29
HUP9600455A2 (en) 1996-12-30
AR003923A1 (es) 1998-09-30
EP0728481A2 (de) 1996-08-28
AU4561596A (en) 1996-09-05
IL117247A0 (en) 1996-06-18
NZ286058A (en) 1998-09-24

Similar Documents

Publication Publication Date Title
FI981591L (fi) AIDS:n hoidossa käyttökelpoisia HIV-proteaasi-inhibiittoreita
RU95106823A (ru) Сукциноиламиногидроксиэтиламиносульфонамиды, фармацевтическая композиция, способ ингибирования ретровирусной протеазы, способ лечения ретровирусной инфекции способ лечения спида
NO954427D0 (no) Hiv-proteaseinhibitorer som er anvendbare for behandling av AIDS
NO893400L (no) Hiv protease inhibitorer egnet for behandling av aids.
BG98902A (bg) Имидазолови производни и тяхната употреба като инхибитори на цитокин
FI954580L (fi) HIV-proteaasin estäjiä farmaseuttisissa yhdistelmissä käytettäväksi AIDSin hoitoon
EP1210941A3 (en) Pharmaceutical compositions containing ritonavir (ABT-538) in combination with indinavir (MK-639) and their use for treating AIDS
ES2191102T3 (es) Heterociclos de peptidilo utiles en el tratamiento de las afecciones relacionadas con la trombina.
MD1507F2 (en) Inhibitors, pharmaceutical composition on base thereof and process for HIV protease inhibition
DK0951473T3 (da) Cyclosporinderivat, fremstilling af dette og farmaceutiske præparater indeholdende dette
NO954635D0 (no) Ribozymgenterapi for HIV infeksjoner og AIDS
DK0760848T3 (da) Lactobacillusstammer af menneskelig oprindelse, deres sammensætninger og anvendelse deraf
DE60123276D1 (de) Piperazinderivate zur behandlung bakterieller infektionen
MX9700538A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares.
DK0703786T3 (da) Anvendelse af nona- og dekapeptider til fremstilling af et lægemiddel til behandling af AIDS
NO960775D0 (no) Anvendelse av kinoksaliner i kombinasjon med proteaseinhibitorer som legemiddel for behandling av AIDS og/eller HIV-infeksjoner
DK1332757T3 (da) Komprimeret tabletformulering indeholdende efavirenz
NO993670L (no) Quinoksalin i trippelkombinasjon med proteaseinhibitorer og reverse transkriptaseinhibitorer som medikamenter for behandling av AIDS
NO934721D0 (no) Hemmere av HIV-protease som er nyttige for behandling av AIDS
DK0825857T3 (da) Anvendelse af gabapentin og derivater deraf til behandling af mani og bipolær lidelse
NO934720L (no) Nye HIV protease inhibitorer
TR200401363T4 (tr) DNA viral enfeksiyonlarının tedavisi
ES2105605T3 (es) Antagonistas de taquiquinina, su preparacion y utilizacion en formulaciones farmaceuticas.
DE69628819D1 (de) Kombinationstherapie der hiv-infektion unter verwendung des hiv-protease inhibitors indinavir und des inhibitors der reversen transkriptase 3 tc zusammen mit azt.
DK0859613T3 (da) Anvendelse af flupirtin til forebyggelse og behandling af sygdomme, som er forbundet med beskadigelse af det hæmopoietiske cellesystem

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application